What's Going On With BridgeBio Pharma Stock Today?
Portfolio Pulse from Vandana Singh
BridgeBio Pharma Inc (BBIO) presented detailed results from its Phase 3 ATTRibute-CM study of acoramidis for ATTR-CM at the European Society of Cardiology Congress 2023. The results showed a highly statistically significant result, an 81% survival rate on acoramidis, and a highly statistically significant treatment effect. The company plans to submit its marketing application to the FDA before the end of 2023. Despite the positive results, BBIO shares are down 4.65% at $28.29.
August 28, 2023 | 6:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Despite positive results from its Phase 3 study of acoramidis, BridgeBio Pharma's stock is down 4.65%. The company plans to submit its marketing application to the FDA before the end of 2023.
The stock price of BridgeBio Pharma has fallen despite the company announcing positive results from its Phase 3 study of acoramidis. This could be due to a variety of factors, including market conditions or investor sentiment. However, the company's plan to submit its marketing application to the FDA before the end of 2023 could potentially boost the stock in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100